Concepedia

Christophe Parsy

CP

Statistics

Publications

11

Citations

316

H-Index

11

Active since

1999

Affiliations

Idera Pharmaceuticals (United States)(Current)

Montpellier GenomiX

Merck & Co., Inc., Rahway, NJ, USA (United States)

Solvay (United Kingdom)

University of Patras

Christophe Parsy is an author at Idera Pharmaceuticals (United States) specializing in drug discovery, medicinal chemistry, and antiviral structure-activity relationships.

ORCID

Publications per year

1999–2018

11

Publications

11

Discovery of the Aryl-phospho-indole IDX899, a Highly Potent Anti-HIV Non-nucleoside Reverse Transcriptase Inhibitor

Cyril B. Dousson, François-René Alexandre, Agnès Amador et al. · Journal of Medicinal Chemistry · 2016 · 73 citations

, , +17

A familial case of Keratitis-Ichthyosis-Deafness (KID) syndrome with the GJB2 mutation G45E

Laurence Jonard, Delphine Feldmann, Christophe Parsy et al. · European Journal of Medical Genetics · 2007 · 57 citations

, , +9

N,N-Dialkylalloxans—a new class of catalyst for dioxirane epoxidations

Andrew J. Carnell, R. A. W. Johnstone, Christophe Parsy et al. · Tetrahedron Letters · 1999 · 43 citations

, , +5

The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2′-α-chloro-2′-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors

François-René Alexandre, Eric Badaroux, John P. Bilello et al. · Bioorganic & Medicinal Chemistry Letters · 2017 · 33 citations · Full text

, , +16

Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320

Christophe Parsy, François-René Alexandre, Valérie Bidau et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 27 citations

, , +14

1–5 of 11